Revolution Medicines (RVMD) said Wednesday the first patient has been dosed in a phase 3 trial evaluating daraxonrasib in patients with previously treated, locally advanced or metastatic RAS mutant non-small cell lung cancer compared to docetaxel chemotherapy.
The trial is expected to enroll around 420 patients, with dual primary endpoints of progression-free survival and overall survival, the company said.
The decision to evaluate daraxonrasib as a monotherapy was informed by early evidence from a single-arm trial showing that the compound had an acceptable safety profile and encouraging antitumor activity, the company said.
Revolution Medicines' shares rose by more than 2% in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.